134 related articles for article (PubMed ID: 33675324)
1. Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz MÁ; Aliño SF; Montesinos P
Pharmacogenet Genomics; 2021 Aug; 31(6):133-139. PubMed ID: 33675324
[TBL] [Abstract][Full Text] [Related]
2. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz M; Aliño SF; Montesinos P
Leuk Lymphoma; 2021 Mar; 62(3):659-668. PubMed ID: 33135528
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
[TBL] [Abstract][Full Text] [Related]
4. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Hervás D; Boluda B; García-Robles A; Rodríguez-Veiga R; Martín-Cerezuela M; Cervera J; Sendra L; Sanz J; Miguel A; Lorenzo I; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 May; 58(5):1197-1206. PubMed ID: 27701910
[TBL] [Abstract][Full Text] [Related]
5. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
6. Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Rodríguez-Veiga R; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2018 Apr; 18(2):301-307. PubMed ID: 28485375
[TBL] [Abstract][Full Text] [Related]
7. Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia.
He H; Xu YJ; Yin JY; Li X; Qu J; Xu XJ; Liu ZG; Zhou F; Zhai M; Li Y; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):400-7. PubMed ID: 24684492
[TBL] [Abstract][Full Text] [Related]
8. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
9. Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenet Genomics; 2017 Jul; 27(7):270-274. PubMed ID: 28570300
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
[TBL] [Abstract][Full Text] [Related]
12. [Relationships between the gene polymorphisms of drug metabolizing enzymes and the outcome of the first induction chemotherapy in patients with de novo acute myeloid leukemia].
Wang N; Han JL; Mi YC; Xiao ZJ; Feng SZ; Zhou YL; Wang JX; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):327-31. PubMed ID: 21518482
[TBL] [Abstract][Full Text] [Related]
13. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.
Jamieson D; Cresti N; Bray J; Sludden J; Griffin MJ; Hawsawi NM; Famie E; Mould EV; Verrill MW; May FE; Boddy AV
Pharmacogenet Genomics; 2011 Dec; 21(12):808-19. PubMed ID: 21946896
[TBL] [Abstract][Full Text] [Related]
14. XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients.
El-Tokhy MA; Hussein NA; Bedewy AM; Barakat MR
Hematology; 2014 Oct; 19(7):397-403. PubMed ID: 24284041
[TBL] [Abstract][Full Text] [Related]
15. [Polymorphisms of RAD51(G135C) and XRCC3(C241T) genes and correlations thereof with prognosis and clinical outcomes of acute myeloid leukemia].
Liu L; Yang L; Zhang Y; Xu ZF; Yu MH; Wang JX; Xiao ZJ
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):378-82. PubMed ID: 18581889
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE
Am J Hematol; 2015 Sep; 90(9):796-9. PubMed ID: 26089240
[TBL] [Abstract][Full Text] [Related]
19. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
